Over the past decade, more than 12 genes have been identified to cause hereditary predispositions to hematologic malignancies. These syndromes are characterized by an increased risk to develop myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or aplastic anemia (AA) at young ages, with various phenotypic features including peripheral cytopenias, immune dysfunction and skeletal defects. In 2013, Churpek et al. proposed a referral algorithm which consists of certain criteria for identifying leukemia patients who may benefit from genetic assessment for these hereditary syndromes. These criteria assess personal history of cytopenias, skin or nail abnormalities, immune deficiencies/atypical infections, and other associated clinical characteristics. The algorithm also assesses family history of leukemia and personal/family history of other malignancies.
iv Regarding clinical/medical record documentation of referral criteria, three hundred and sixty-four (59.9%) individuals reported at least one first or second-degree relative with cancer. Thirty-one (5.1%) individuals reported a family history of leukemia, which was also the most consistently reported criteria in the medical record (n=580, 95.4%). Overall, 406 individuals (66.8%) had insufficient documentation to determine whether any criteria were met. Two hundred and two (33.2%) individuals met at least one of the proposed criteria for genetic counseling referral; however, only nine received a referral (4.5%) to genetic counseling. Increased documentation of the presence or absence of phenotypic features associated with these hereditary syndromes is necessary to better assess the applicability of these criteria, and to ensure that individuals receive appropriate referral for cancer genetics Proposed Algorithm for identifying individuals for referral for comprehensive cancer risk assessment…………………..…………4 Table 1 Demographics…………………………………………………..7 Table 2 Documentation of evaluated criteria………………………….9 Table 3 Family history of MDS/AML/AA/ALL…….………………...10 Table 4 Comparison between patients who met criteria and those who could not be determined ……………………………..…….11 Table 5 Referral criteria and subsequent referral to genetic counseling………………………………………………………13
Introduction
Leukemia is the tenth most common malignancy in the United States with an estimated 60,140 new cases diagnosed in 2016 [1] . Familial occurrences of leukemia have been documented in the literature and first-degree relatives of individuals with leukemia carry an estimated 2.5-6 fold increased lifetime risk of leukemia depending on the type of leukemia in the family [6, 7] . In fact, approximately 10-20% of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and aplastic anemia (AA) are related to newly-described hereditary predisposition syndromes [2] [3] [4] [5] .
Over the past decade, clinical investigations into families with multiple close relatives with leukemia have identified more than a dozen genes related to inherited predispositions to MDS and AML [3] . clinical bleeding in both adults and children [8, 9] . Additional phenotypes include primary lymphedema, deafness, cutaneous warts, low CD4/CD8 T cell ratio and mycobacterial infections [10] [11] [12] , which can be seen in patients with germline GATA2 mutations.
Recently, research has revealed that previously described conditions like FA and DC have more variable phenotypic expressivity than previously described, with 25-40% of individuals with FA, and 10-25% of individuals with DC, having no physical characteristics suggestive of these conditions [13, 14] . Additionally, individuals with IBMFS who do not show classic physical characteristics are more likely to have delayed diagnosis of MDS/AML/AA, often in adulthood [13] . This variability makes IBMFS difficult to diagnose in individuals who do not display the characteristic phenotype. Timely diagnosis is critical for treatment of MDS/AML/AA, as patients with IBMFS and familial AML/MDS syndromes have poor outcomes from hematopoietic stem cell transplantation (HSCT) due to use of a related donor with the same germline mutation and/or increased toxicity from high-intensity transplant conditioning regimens [15] [16] [17] .
The complications arising from HSCT transplantation from a related donor illustrates the importance of a thorough family history for these at risk individuals. In 2014, the American Society of Clinical Oncology (ASCO) published an expert opinion statement regarding the collection and use of family history in oncology assessments and suggested that the minimum family history obtained should include cancer history of first-and seconddegree relatives, including the type of primary cancer and age of diagnosis [14] . Although not all patients report an accurate family history, a study by Ziogas and Anton-Culver showed that most patient reports of family history are reliable, especially when reporting cancer history of first-degree relatives [18] . According to the ASCO statement, clinicians should be able to assess a family history to help determine if further evaluation for hereditary predisposition is warranted; however, a study by Sussner et al. revealed that only 1.7% of surveyed physicians felt they could accurately interpret a family history and make appropriate recommendations [19, 20] . While previously considered exceedingly rare, the recent discovery of multiple hematologic malignancy predisposition syndromes requires increased clinical provider awareness. For optimal identification and appropriate referral of patients at risk of hereditary cancer syndromes, an accurate, detailed family history is critical to identify at-risk patients and families, as well as to help guide treatment and management.
With the identification of these predisposition genes, researchers have sought to understand how frequently these germline mutations occur in patients with leukemia. To date, no studies have sought to evaluate the clinical applicability of these criteria to an unselected adult population of leukemia patients. We aim to assess the proposed algorithm against a large unselected cohort of patients with MDS/AML/AA to determine if the characteristics needed to identify these patients for genetic counseling and risk assessment are reported in the medical record. Identifying these individuals is of utmost importance for personalized treatment strategies to maximize positive outcomes and minimize toxicity.
Materials and Methods

Patient Selection
We 
Statistical Analyses
Patient demographics, clinicopathologic characteristics, and personal and family history variables were analyzed. We evaluated 608 patients with MDS/AML/AA for the proposed criteria ( Figure 1 ) to determine if they met the proposed criteria, and whether eligible patients were recommended for cancer genetic risk assessment. 
Results
Demographics
Clinical data and demographic information from 608 individuals diagnosed with AML/MDS/AA seen at our institution from March 1, 2014-December 31, 2014 are described in Table 1 . The criterion with the highest reported documentation was family history of leukemia, noted in 95.4% (n=580) of individuals.
Family history of MDS/AML/AA
Thirty-one (16.2%) individuals who met criteria reported a family history of MDS/AML/AA or acute lymphoblastic leukemia (ALL) ( Table 3) . 
Comparison between individuals who met criteria and those who could not be determined
Overall, 406 (66.8%) individuals had insufficient documentation to determine whether any criteria were met. Two hundred and two (33.2%) individuals met at least one of the proposed criteria for genetic counseling referral. Due to insufficient documentation, no individuals were classified as not meeting criteria [ Table 4 ]. 
Referral to genetic counseling
Of the 202 individuals that met at least one criteria for a cancer genetics referral according to the proposed algorithm, 166 (82.2%) met one criteria, 30 (14.8%) met 2, 5 (2.5%) met 3, and only one patient (0.5%) met 4 criteria [ Table 5 ]. 
p=0.002
Only 9 patients (4.5%) who met criteria received a referral for clinical cancer genetics risk assessment The difference between number of criteria met and the likelihood for subsequent genetics referral was statistically significant (p=0.002) with those meeting more criteria being less likely to have been referred to genetics.
Additional Criteria
In addition to the criteria proposed by Churpek et al., we assessed the somatic mutation profile within this MDS/AML/AA cohort. In our cohort, 29 (4.8%) individuals were found to have >2 somatic mutations in three genes known to be associated with hereditary hematologic malignancies and tested within our current myeloid malignancy panel: CEBPA, RUNX1 and GATA2. Of 10 individuals with >2 CEBPA mutations, only four met one of the proposed Churpek et al. criteria. One patient with biallelic GATA2 mutations met two criteria. Of the 18 patients with >2 RUNX1 mutations, five met one of the referral criteria.
We also assessed young age at MDS/AML/AA diagnosis, specifically individuals diagnosed prior to age 40. In our cohort, 66 (10.85%) individuals were diagnosed ≤40 years. Of those, only 17 (%) met at least one of the Churpek criteria.
Discussion
We reviewed the medical records of 608 individuals to evaluate the criteria proposed This is consistent with current national guidelines that recommend genetic counseling referrals based on family history of these specific malignancies (i.e. BRCA1 and BRCA2 evaluation). While not directly related to assessing for inherited leukemia syndromes, it is important to note that personal and family history of non-hematologic malignancies are referenced in the Churpek algorithm and should be assessed according to the ASCO guidelines, and followed up by appropriate cancer genetics evaluation (14) . Only 4.5% of patients who met at least one-referral criteria received a genetics referral. The trends seen in Table 6 illustrate that as the number of criteria increased, so did the percentage of patients referred. The lack of cancer genetics referrals, coupled with the lack of documented personal and family history criteria makes it difficult to assess the true applicability of the criteria.
One principal researcher reviewed all 608 charts and human error cannot be excluded as a possible limitation of this study. Additionally, study design was a possible limitation to this study. . This is important considering 6 individuals in this study with biallelic CEBPA mutations met no additional testing criteria, but have an increased risk for an inherited susceptibility. Based on previous estimates, it is likely that at least one individual in the cohort had a germline CEBPA mutation. We propose that considering ≥2 somatic mutations in CEBPA, RUNX1 and GATA2 as an additional referral criterion may be warranted, as it would potentially increase the detection of individuals who otherwise have no additional indications for genetic risk assessment.
Additionally, the presence of a variant allele frequency suggestive of germline inheritance (~50%) is an important question for future analysis regarding identifying patients at risk for germline mutations. We also assessed young age at MDS/AML/AA diagnosis, specifically individuals diagnosed prior to age 40 since individuals with IBMFS are at a significantly increased risk to develop BMF before the age of 40 [16] . We propose that age dx <40 and/or the presence of >2 somatic mutations should be considered as additional criteria when assessing leukemia patients for referral for cancer genetics risk assessment.
Suggestions to increase documentation include incorporating criteria assessment into the EMR, or obtaining information directly from patients via a short intake form/questionnaire. Further studies need to assess the applicability of these criteria and may benefit from including suggested additional criteria like molecular testing results and age of diagnosis prior to age 40. Further studies are needed to determine which combination of criteria yields the highest association with subsequent positive germline testing results.
National guidelines for referral criteria for inherited leukemia susceptibility syndromes would likely increase detection of families with hereditary predispositions to hematologic malignancies.
Conclusion
One-third of individuals met at least one criteria for a cancer genetics referral based on the proposed algorithm, while the remainder could not be determined based on insufficient information present in the medical record. Ultimately, only nine individuals presenting during this nine-month interval meeting criteria received genetic counseling referrals. The presence or absence of proposed criteria must be documented in the medical record in order to assess clinical applicability in the leukemia population. Increased and timely detection of these families is important, as it would allow for more tailored transplant donor selection, treatment, anticipatory guidance counseling, and increased screening for at risk family members. 338 Hearthstone Lane Coppell, TX 75019
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